Form 4: Alnylam Pharmaceuticals Executive Pushkal Garg Reports Stock Transactions

CMO & EVP Dev & Med Affairs Pushkal Garg reports acquisition of restricted stock units and sales of Alnylam Pharmaceuticals (ALNY) common stock, including transactions under a 10b5-1 trading plan.

Summary

• Pushkal Garg, CMO & EVP Dev & Med Affairs at Alnylam Pharmaceuticals, reported transactions involving the company's common stock.
• On March 3, 2025, Garg acquired 14,137 restricted stock units (RSUs) and sold shares of common stock at prices ranging from $242.37 to $248.36.
• These sales were made to cover tax obligations related to the vesting of RSUs and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2024.
• On March 3, 2025, Garg also acquired 7,819 stock options with an exercise price of $243.53, expiring on March 3, 2035.
• On March 4, 2025, Garg sold shares of common stock at prices ranging from $239.25 to $242.7.
• Following these transactions, Garg directly owns 25,740 shares of common stock, 431 shares indirectly through a managed account, and 250 shares indirectly through a trust.
• Garg also directly owns 7,819 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are routine and conducted under a pre-arranged plan. The acquisition of RSUs and options is a positive sign, while the sale of shares is likely for tax purposes.

Positives

• The acquisition of RSUs and stock options indicates a continued investment in the company's future by a key executive.

Negatives

• The sale of shares, even under a pre-arranged plan, could be interpreted negatively by some investors, although it is primarily for tax obligations.

Risks

• Continued sales of shares by executives, even under 10b5-1 plans, could create downward pressure on the stock price if perceived negatively by the market.

Industry Context

Insider transactions are a normal part of corporate governance, and the use of 10b5-1 plans is a common practice to avoid accusations of trading on non-public information. Investors often monitor these filings for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Similar transactions are routinely disclosed by executives at comparable pharmaceutical companies like Moderna (MRNA) and BioNTech (BNTX).
• The vesting schedules and terms of the RSUs and stock options appear consistent with standard equity compensation practices in the biotech industry.
• The use of a 10b5-1 trading plan is a common and accepted method for executives to manage their stock holdings while avoiding potential insider trading concerns, aligning with practices seen at companies like Regeneron (REGN) and Vertex Pharmaceuticals (VRTX).

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on how they interpret the insider activity.
• Employees may view the RSU grants as a positive sign of the company's commitment to its workforce.

Key Dates